Doxazosin (drug) — Competitive Intelligence Brief

Doxazosin (drug) (Doxazosin (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular; Urology.

marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular; Urology Small molecule

Target snapshot

Doxazosin (drug) (Doxazosin (drug)) — Japan Heart Foundation. Doxazosin is an alpha-1 adrenergic receptor antagonist that blocks norepinephrine signaling in blood vessels and the prostate, causing vasodilation and smooth muscle relaxation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxazosin (drug) TARGET	Doxazosin (drug)	Japan Heart Foundation	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Xylometazoline - intranasal application	Xylometazoline - intranasal application	Association Asthma, Bulgaria	marketed	Alpha-1 adrenergic agonist (nasal decongestant)	Alpha-1 adrenergic receptor
Visine® for Contacts®	Visine® for Contacts®	Merck Sharp & Dohme LLC	marketed	Ophthalmic decongestant	Alpha-1 adrenergic receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)
Norepinephrine (static group)	Norepinephrine (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Epinephrine Injection	Epinephrine Injection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Catecholamine; alpha and beta adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Experimental dosing of labetalol	Experimental dosing of labetalol	Albany Medical College	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class